GLP-C – 10mg

GLP-C is First Class Science’s research-grade preparation of cagrilintide, a synthetic long-acting analog of human amylin, a hormone co-secreted with insulin that participates in glucose and appetite regulation. Published clinical and preclinical research has examined cagrilintide’s amylin-receptor activity, including in combination with GLP-1 receptor agonists, and the summary below reflects that literature for research reference only.

What is GLP-C?

Cagrilintide is engineered from native amylin with a fatty-acid side chain that promotes albumin binding, a modification reported to extend its half-life and support once-weekly dosing regimens studied in clinical trials. Researchers have examined cagrilintide’s activity at amylin receptors, which are proposed to act on central appetite-regulation circuits distinct from, but complementary to, GLP-1 receptor signaling.

Randomized clinical trials have examined cagrilintide administered alone and in combination with semaglutide (a GLP-1 receptor agonist), reporting body-weight and metabolic measures in defined trial populations. Researchers frequently study amylin-pathway and GLP-1-pathway agonists together because the two hormone systems are believed to act on overlapping but mechanistically distinct appetite-regulation circuits.

Chemical Identity

First Class Science notes molecular formula and weight figures for cagrilintide vary slightly across published sources depending on salt form; researchers should confirm exact analytical specifications against the Certificate of Analysis provided with each batch.

Purity & Quality

First Class Science supplies GLP-C at 99% purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at https://firstclassscience.com/certificate-of-analysis/. Store lyophilised compound at −20°C for long-term stability; refrigerate at 2–8°C after reconstitution and use within 4–6 weeks.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Research Applications

Amylin-Receptor & Appetite-Regulation Research

Published clinical trials have examined cagrilintide’s association with body-weight and food-intake measures in defined adult trial populations, attributed by study authors to amylin-receptor engagement in central appetite-regulation circuits distinct from GLP-1 receptor signaling.

Combined Amylin/GLP-1 Pathway Research

Clinical research has also examined cagrilintide administered alongside GLP-1 receptor agonists such as semaglutide, reporting metabolic and body-weight measures researchers have attributed to complementary activity across the two receptor systems in the trial populations studied. This is described here as parallel-pathway research context, not as a property or claim about this individual research compound in combination with any other substance.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or non-U.S. clinical contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.